Symposium Agenda

July 10, 2006

8:45 to 9:00: Welcome and Introductions, Robert Rubin, MD, InHealth Research Council Chairman and Board Member

At risk in current public policy discussions is the continued flow of innovative medical technologies (defined here to exclude pharmaceuticals and biotech) in the diagnosis and treatment of patients - and the continuing health of an innovative sector of the U.S. economy. Aging "Baby Boomers," advancing medical capabilities, and rising costs, offer both opportunities and threats. This InHealth Symposium seeks to deepen understanding of the challenges ahead and to thereby create a platform for understanding potential solutions.

9:00 to 10:15: Technology Saves Lives, Delivers Economic Benefits and Costs Money: Balancing the Values Presenters: Dan Crippen, former Director of Congressional Budget Office; Frank Lichtenberg, PhD., Courtney C. Brown Professor of Business, Columbia University. Both presenters will provide perspectives regarding the value and role of medical technology and the cost consequences and challenges this poses. They will comment on studies on medical technology's effectiveness and proposals for funding medical technology innovation.

• Responders: Jim Bradford, dean of the Vanderbilt Owen Graduate School of Management; Myrl Weinberg, President, National Health Council; Randy Johnson, Director, Motorola
• Facilitated audience discussion

10:15 to 10:30: Break

10:30 to 11:45: Sustaining Innovation: The Innovator's Perspective

• Presenter: Ali Rezai, M.D., Cleveland Clinic; Elizabeth Weatherman, Managing Director, Warburg Pincus, LLC: Dr. Rezai is a world renowned physician and innovator. He will identify from first-hand experience the most important requirements from the innovator's perspective for successfully translating research and a product to success in the market. As is the Managing Director of the leading direct equity investor in healthcare, Bess Weatherman has first hand experience in helping innovators finance and bring to market many successful breakthrough medical technologies.
• Responders: Dan Schultz, Director, CDRH; Stephen Northrup, Health Counsel, Senate Committee on Health, Education, Labor and Pensions; Joel White, Staff Director, House Ways and Means Health Subcommittee
• Facilitated audience discussion

12:00 to 1:00: Lunch

1:00 to 2:15: Accelerating Solutions for Patients: Regulatory Reform

• Presenters: Bruce Burlington, M.D., Former Director, FDA's Center for Device and Radiological Health (CDRH), currently Executive Vice President, Quality, Regulatory, and Safety for Wyeth Pharmaceuticals; David Feigel, M.D., Former Director FDA's CDRH, currently consultant: Feigel reflects on his experience at FDA's CDRH and areas of potential improvement so as to achieve greater predictability and speed in gaining product approval as well as assuring patient safety. This will include an honest discussion of what is working well and what represents an opportunity for improvement in the FDA pre- and post- market processes.
• Responders:Patricia Shrader, Esq., Senior Vice President, Corporate Regulatory and External Affairs; Jack Lasersohn, General Partner, The Vertical Group
• Facilitated audience discussion

2:15 to 2:30: Break

2:30 to 3:45: What Can and Can't We Afford?

• Presenters: Mark McClellan, MD, Administrator, Centers for Medicare and Medicaid Services: Dr. McClellan is leading a payment system transformation at CMS where increasingly payment will be linked to performance. Rewarding efficiency, reporting quality measures, gainsharing, coverage with evidence, are examples of initiatives Dr. McClellan is driving that hold significant implications for medical technology innovation. This session will be an open dialogue on the issues, concerns and future of "value-based" purchasing.
• Responders: Tom Ault, Principal, Health Policy Alternatives; Daniel Evans, CEO, Clarian Hospital System, Indianapolis
• Facilitated audience discussion

3:45 to 4:00: What have we learned and where do we go from here? Robert Rubin, MD.